T. Rowe Price Investment Management, Inc. filed a Schedule 13G with the SEC on November 16, 2026, disclosing a beneficial ownership position in Aktis Oncology Inc. common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: T. Rowe Price Investment Management, Inc. reported beneficial ownership of 3,333,026 shares of Aktis Oncology Inc. common stock.
  • Percent of class: The 3,333,026 shares represent 6.2% of the class, according to the filing.
  • Sole voting and dispositive power: The filing discloses sole voting power and sole dispositive power over all 3,333,026 shares, with no shared voting or dispositive power reported.
  • Triggering event date: The date of the event requiring the filing is listed as September 30, 2026.
  • Filer classification: T. Rowe Price Investment Management, Inc. is identified in the filing as an investment adviser, organized in Maryland, with a principal business address of 1307 Point Street, Baltimore, MD 21231.

T. Rowe Price Investment Management Discloses Position in Aktis Oncology Common Stock

T. Rowe Price Investment Management, Inc. filed a Schedule 13G disclosing its holdings in Aktis Oncology Inc. (NASDAQ:AKTS), a company with principal executive offices listed at 17 Drydock Avenue, Suite #17-401, Boston, MA. The filing was signed by Ellen York, Vice President, and dated November 16, 2026. The event triggering the filing occurred on September 30, 2026.

According to the filing, T. Rowe Price Investment Management, Inc. holds 3,333,026 shares of Aktis Oncology common stock (CUSIP 01021M104), constituting 6.2% of the class. The filing reports that all 3,333,026 shares carry sole voting power and sole dispositive power with no shared voting or dispositive power over any portion of the position.

The filing includes a certification stating that, to the best of the filer's knowledge and belief, "the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." The filing also states that it "shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied."

What Was Disclosed

T. Rowe Price Investment Management, Inc. disclosed a 6.2% beneficial ownership stake of 3,333,026 shares of Aktis Oncology Inc. common stock via Schedule 13G, with the triggering event dated September 30, 2026, and the filing signed on November 16, 2026.